alendronate has been researched along with Aging in 21 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Many drugs for the treatment of osteoporosis have also been associated with increased risks of serious adverse events." | 2.52 | Osteoporosis: the emperor has no clothes. ( Aspenberg, P; Järvinen, TL; Michaëlsson, K; Sievänen, H, 2015) |
| "Treatment with alendronate improved trabecular volume and number by reducing bone resorption, although bone formation was also reduced through coupling of bone remodeling." | 1.34 | Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture. ( Andresen, CJ; Bagi, CM; Berryman, E; Hanson, N; Moalli, M; Olson, E; Shen, V; Volberg, M, 2007) |
| "This study investigates the role of bone resorption in defining interdigitations characteristic of cranial suture waveform." | 1.33 | Role of the osteoclast in cranial suture waveform patterning. ( Byron, CD, 2006) |
| "The aim of the study was to assess the long-term anabolic effect of the parathyroid hormone (PTH) analog SDZ PTS 893 in a dose-response manner, and to determine the ability of the antiresorptive agents estradiol and alendronate to maintain bone mass after withdrawal of SDZ PTS 893." | 1.30 | Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats. ( Gasser, JA; Mosekilde, LI; Thomsen, JS, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yao, W | 2 |
| Guan, M | 1 |
| Jia, J | 1 |
| Dai, W | 1 |
| Lay, YA | 1 |
| Amugongo, S | 1 |
| Liu, R | 1 |
| Olivos, D | 1 |
| Saunders, M | 1 |
| Lam, KS | 1 |
| Nolta, J | 1 |
| Olvera, D | 1 |
| Ritchie, RO | 1 |
| Lane, NE | 2 |
| Järvinen, TL | 1 |
| Michaëlsson, K | 1 |
| Aspenberg, P | 1 |
| Sievänen, H | 1 |
| Lorentzon, M | 1 |
| Cummings, SR | 1 |
| Naruse, K | 1 |
| Uchida, K | 1 |
| Suto, M | 1 |
| Miyagawa, K | 1 |
| Kawata, A | 1 |
| Urabe, K | 1 |
| Takaso, M | 1 |
| Itoman, M | 1 |
| Mikuni-Takagaki, Y | 1 |
| Verhaar, HJ | 1 |
| Inose, H | 1 |
| Zhou, B | 1 |
| Yadav, VK | 1 |
| Guo, XE | 1 |
| Karsenty, G | 1 |
| Ducy, P | 1 |
| Ito, M | 2 |
| Azuma, Y | 2 |
| Takagi, H | 2 |
| Komoriya, K | 2 |
| Ohta, T | 2 |
| Kawaguchi, H | 2 |
| McHugh, NA | 1 |
| Vercesi, HM | 1 |
| Egan, RW | 1 |
| Hey, JA | 1 |
| Kamimura, T | 1 |
| Fukunaga, M | 1 |
| Greenspan, SL | 1 |
| Beck, TJ | 1 |
| Resnick, NM | 1 |
| Bhattacharya, R | 1 |
| Parker, RA | 1 |
| Byron, CD | 1 |
| Bagi, CM | 1 |
| Volberg, M | 1 |
| Moalli, M | 1 |
| Shen, V | 1 |
| Olson, E | 1 |
| Hanson, N | 1 |
| Berryman, E | 1 |
| Andresen, CJ | 1 |
| Guy, JA | 1 |
| Shea, M | 1 |
| Peter, CP | 1 |
| Morrissey, R | 1 |
| Hayes, WC | 1 |
| Myers, ER | 1 |
| Wilson, SE | 1 |
| Shiflett, S | 1 |
| Cooke, CE | 1 |
| Beauchesne, MF | 1 |
| Miller, PF | 1 |
| Thomsen, JS | 1 |
| Mosekilde, LI | 1 |
| Gasser, JA | 1 |
| Hamerman, D | 1 |
| Trémollières, F | 1 |
8 reviews available for alendronate and Aging
| Article | Year |
|---|---|
Osteoporosis: the emperor has no clothes.
Topics: Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Evidence-Based Medicine; Female; | 2015 |
Osteoporosis: the evolution of a diagnosis.
Topics: Absorptiometry, Photon; Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Fracture | 2015 |
[Bone mass measurement and evaluation of therapeutical response].
Topics: Absorptiometry, Photon; Aging; Alendronate; Biomarkers; Bone Density; Calcium; Estrogen Replacement | 2004 |
Biomechanics of osteoporosis and vertebral fracture.
Topics: Aged; Aged, 80 and over; Aging; Alendronate; Animals; Bone Density; Female; Humans; Middle Aged; Ost | 1997 |
Osteoporosis: a focus on treatment.
Topics: Accidental Falls; Aged; Aging; Alendronate; Bone Density; Calcitonin; Contraindications; Estrogen Re | 1997 |
Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
Topics: Aging; Alendronate; Bone Density; Clinical Trials as Topic; Data Collection; Etidronic Acid; Female; | 1999 |
Considerations of osteoporosis prevention in an aging society.
Topics: Aging; Alendronate; Bone Density; Estrogens; Female; Humans; Osteoporosis, Postmenopausal | 2000 |
[Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].
Topics: Aging; Alendronate; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Mi | 2001 |
1 trial available for alendronate and Aging
| Article | Year |
|---|---|
Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial.
Topics: Aged; Aging; Alendronate; Body Weight; Bone and Bones; Bone Density; Densitometry; Diphosphonates; D | 2005 |
12 other studies available for alendronate and Aging
| Article | Year |
|---|---|
Reversing bone loss by directing mesenchymal stem cells to bone.
Topics: Aging; Alendronate; Animals; Bone and Bones; Bone Resorption; Cell Differentiation; Cell Movement; D | 2013 |
Targeted delivery of mesenchymal stem cells to the bone.
Topics: Aging; Alendronate; Animals; Bone and Bones; Dipeptides; Estrogens; Immunocompetence; Mesenchymal St | 2015 |
Alendronate does not prevent long bone fragility in an inactive rat model.
Topics: Aging; Alendronate; Animals; Bone Density; Female; Fractures, Bone; Immobilization; Osteoporosis; Ov | 2016 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Ag | 2008 |
Efficacy of serotonin inhibition in mouse models of bone loss.
Topics: Aging; Alendronate; Animals; Bone and Bones; Bone Resorption; Disease Models, Animal; Dose-Response | 2011 |
Curative effect of combined treatment with alendronate and 1 alpha-hydroxyvitamin D3 on bone loss by ovariectomy in aged rats.
Topics: Aging; Alendronate; Animals; Bone Density; Drug Therapy, Combination; Female; Hydroxycholecalciferol | 2002 |
In vivo rat assay: bone remodeling and steroid effects on juvenile bone by pQCT quantification in 7 days.
Topics: Aging; Alendronate; Animals; Bone and Bones; Bone Density; Bone Development; Bone Remodeling; Dose-R | 2003 |
Preventive effects of sequential treatment with alendronate and 1 alpha-hydroxyvitamin D3 on bone mass and strength in ovariectomized rats.
Topics: Aging; Alendronate; Animals; Bone Density; Compressive Strength; Drug Therapy, Combination; Female; | 2003 |
Role of the osteoclast in cranial suture waveform patterning.
Topics: Acid Phosphatase; Age Factors; Aging; Alendronate; Animals; Animals, Newborn; Bone Density Conservat | 2006 |
Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture.
Topics: Absorptiometry, Photon; Aging; Alendronate; Animals; Bone and Bones; Bone Density Conservation Agent | 2007 |
Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties.
Topics: Aging; Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Development | 1993 |
Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats.
Topics: Aging; Alendronate; Animals; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Resorption | 1999 |